Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 1;35(5):554-561.
doi: 10.1097/MOU.0000000000001321. Epub 2025 Jul 15.

Integration of prostate-specific membrane antigen-PET and multiparametric MRI for gross tumour volume definition in localised and locally advanced prostate cancer treated with image-guided radiotherapy

Tessa D van Bergen  1 , Arthur J A T Braat  2 , Cornelis A T van den Berg  1 , Timo F W Soeterik  3
Affiliations
Review

Integration of prostate-specific membrane antigen-PET and multiparametric MRI for gross tumour volume definition in localised and locally advanced prostate cancer treated with image-guided radiotherapy

Tessa D van Bergen et al. Curr Opin Urol. .

Abstract

Purpose of review: This review evaluates recent evidence on the utility of multiparametric MRI (mpMRI), prostate-specific membrane antigen (PSMA) PET, and their combined application for accurately delineating the intraprostatic gross tumour volume (GTV) in patients with primary localised and locally advanced prostate cancer. It further explores the impact of GTV-based dose escalation on treatment-related toxicity and clinical outcomes.

Recent findings: Recent studies suggest that combining PSMA-PET with mpMRI enhances lesion coverage of clinically significant, histopathologically verified intraprostatic tumours and yields higher interobserver agreement. However, this improved sensitivity is offset by reduced specificity, and it remains uncertain whether expanding the GTV to include additional PSMA-PET-defined regions impacts long-term treatment-related toxicity or improves oncological outcomes. Multiple phase I/II trials using PSMA-PET and mpMRI have reported acceptable acute and late toxicity profiles. Nevertheless, extensive data on long-term toxicity and disease outcomes following PSMA-PET-guided interventions remain limited, warranting further investigation to assess its impact.

Summary: The combination of mpMRI and PSMA-PET has been shown to improve coverage of dominant intraprostatic lesion and reduce interobserver variability. While GTVs derived from combined imaging modalities are typically larger than those based on mpMRI alone, hypofractionated focal boost treatments targeting PSMA-PET/mpMRI-defined GTVs have demonstrated acceptable acute toxicity profiles. More data are needed to determine the impact of PSMA-PET expanded GTVs on long-term clinical outcomes.

Keywords: MRI; focal boosting; gross tumour volume; image-guided radiotherapy; prostate cancer; prostate-specific membrane antigen PET.

PubMed Disclaimer

Conflict of interest statement

None related to this work.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011; 60:1133–1139. - PMC - PubMed
    1. Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80:1056–1063. - PubMed
    1. Vogelius IR, Bentzen SM. Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2018; 100:858–865. - PubMed
    1. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 2021; 39:787–796. - PubMed
    1. Groen VH, Haustermans K, Pos FJ, et al. Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer. Eur Urol 2022; 82:252–257. - PubMed

MeSH terms